Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fate Therapeutics (NQ: FATE )

2.110 -0.080 (-3.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics

< Previous 1 2 3 4 5 6 7 8 9 Next >
Fate Therapeutics Inc. (NASDAQ: FATE) Near the Top of Equities by Percentage Gain on 9/18
Via Investor Brand Network
Analyst Ratings for Fate Therapeutics
Via Benzinga
Fate Therapeutics to Present at Upcoming September Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
The Latest Analyst Ratings for Fate Therapeutics
Via Benzinga
Where Fate Therapeutics Stands With Analysts
Via Benzinga
Fate Therapeutics: Q1 Earnings Insights
Via Benzinga
Fate Therapeutics Earnings Preview
Via Benzinga
Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 46 stocks hit new 52-week lows. 
Via Benzinga
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results
From Fate Therapeutics, Inc.
Via GlobeNewswire
15 Analysts Have This to Say About Fate Therapeutics
Via Benzinga
FATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE
From Kahn Swick & Foti, LLC
Via Business Wire
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Why Shares of Fate Therapeutics Soared This Week
The company's shares bounced back after a stock sale last week. 
Via The Motley Fool
Fate ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
FATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE
From Kahn Swick & Foti, LLC
Via Business Wire
Fate Therapeutics to Present at Upcoming June Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire
NASDAQ:FATE Long Term Investor Alert: Investigation of Potential Wrongdoing at Fate Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 05/24/2023 -- An investigation was announced for investors in shares of Fate Therapeutics, Inc. (NASDAQ:FATE) concerning potential breaches of fiduciary duties by certain... 
Via SBWire
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
$1.7M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed slightly higher on Friday, there were a few notable insider trades. 
Via Benzinga
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results
From Fate Therapeutics, Inc.
Via GlobeNewswire
FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 22 Deadline in Securities Class Action – FATE
From The Rosen Law Firm, P.A.
Via Business Wire
FATE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Fate Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)
From The Law Offices of Frank R. Cruz
Via Business Wire
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important March 22 Deadline in Securities Class Action - FATE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important March 22 Deadline in Securities Class Action - FATE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
NASDAQ:FATE Investor Notice: Deadline on March 22, 2023 in Lawsuit Against Fate Therapeutics, Inc
San Diego, CA -- (SBWIRE) -- 03/13/2023 -- The Shareholders Foundation announced that a deadline is coming up on March 22, 2023 in the lawsuit filed for certain investors of Fate Therapeutics, Inc.... 
Via SBWire
Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Fate Therapeutics, Inc. (FATE) Investors of Class Action and Last Few Days to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.